• Research Findings and Conclusion
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/systemic-lupus-erythematosus-treatment-
market-1540
Regional dynamics
North America is expected to be the dominant market in the global SLE treatment market, over
the forecast period. This is owing to relatively higher prevalence of SLE in this region as
compared to other regions. According to study published in the Rheumatology Journal, in May
2017, incidence and prevalence of SLE in North America was 23.2 people per 1, 00,000 and
241 per 1, 00,000 people, respectively. High presence of market players in North America is
also another factor for growth of the market in this region. Key players such as
GlaxoSmithKline, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb in systemic lupus
erythematosus market have high presence in this region.
Competitive landscape
Key players operating in the systemic lupus erythematosus treatment market are
GlaxoSmithKline Plc (GSK), F. Hoffmann-La Roche Ltd, Anthera Pharmaceuticals Inc., Bristol-
Myers Squibb, Eli Lilly, Pfizer Limited, Merck KGaA, Immupharma Plc, Sanofi, Lycera
Corporation, Aurinia Pharmaceuticals Inc., Mylan N.V., and Sandoz International GmbH.
Companies in the market are engaged in developing novel therapy for treatment of systemic
lupus erythematosus, which would also aid in market growth. Immupharma plc’s Lupozor
completed phase 3 clinical trial in December 2017, which earlier was granted with fast track
status by the US FDA. Atacicept from Merck Serono (German based Merck KGaA) completed
phase 2 trial in February 2018. In March 2018, GlaxoSmithKline plc started phase 3 clinical
trial by combining belimumab (Benlysta) with rituximab for treating patients with systemic
lupus erythematosus which is expected to provide efficient treatment for SLE than single
medicine.
To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/
buy-now/1540
Antimalarial is often used in mild SLE conditions, whereas, glucocorticoids and NSAIDS are
commonly used in mild to moderate conditions. These are also preferred treatment in case of
complications associated with SLE, where organs are damaging due to the disease. NSAIDS and